Loading…

Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer

Tertiary lymphoid structures (TLSs) are ectopic lymphoid formations that arise in non-lymphoid tissues due to chronic inflammation. The pivotal function of TLSs in regulating tumor invasion and metastasis has been established across several cancers, such as lung cancer, liver cancer, and melanoma, w...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2024-03, Vol.15, p.1364506-1364506
Main Authors: Liu, Ruiqi, Huang, Xiaoqian, Yang, Shiwei, Du, Wenbo, Chen, Xiaozhou, Li, Huamei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c420t-fcf3f3ca7fef238ff3bf6eb70ab016fc50e6a45c0ec970f5483626cccfb35ee53
container_end_page 1364506
container_issue
container_start_page 1364506
container_title Frontiers in immunology
container_volume 15
creator Liu, Ruiqi
Huang, Xiaoqian
Yang, Shiwei
Du, Wenbo
Chen, Xiaozhou
Li, Huamei
description Tertiary lymphoid structures (TLSs) are ectopic lymphoid formations that arise in non-lymphoid tissues due to chronic inflammation. The pivotal function of TLSs in regulating tumor invasion and metastasis has been established across several cancers, such as lung cancer, liver cancer, and melanoma, with a positive correlation between increased TLS presence and improved prognosis. Nevertheless, the current research about the clinical significance of TLSs in breast cancer remains limited. In our investigation, we discovered TLS-critical genes that may impact the prognosis of breast cancer patients, and categorized breast cancer into three distinct subtypes based on critical gene expression profiles, each exhibiting substantial differences in prognosis (p = 0.0046, log-rank test), with Cluster 1 having the best prognosis, followed by Cluster 2, and Cluster 3 having the worst prognosis. We explored the impact of the heterogeneity of these subtypes on patient prognosis, the differences in the molecular mechanism, and their responses to drug therapy and immunotherapy. In addition, we designed a machine learning-based classification model, unveiling highly consistent prognostic distinctions in several externally independent cohorts. A notable marker gene CXCL13 was identified in Cluster 3, potentially pivotal in enhancing patient prognosis. At the single-cell resolution, we delved into the adverse prognosis of Cluster 3, observing an enhanced interaction between fibroblasts, myeloid cells, and basal cells, influencing patient prognosis. Furthermore, we identified several significantly upregulated genes (CD46, JAG1, IL6, and IL6R) that may positively correlate with cancer cells' survival and invasive capabilities in this subtype. Our study is a robust foundation for precision medicine and personalized therapy, presenting a novel perspective for the contemporary classification of breast cancer.
doi_str_mv 10.3389/fimmu.2024.1364506
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5fa59fb2d65a48bea4e73e7b91c847e7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5fa59fb2d65a48bea4e73e7b91c847e7</doaj_id><sourcerecordid>3033008018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-fcf3f3ca7fef238ff3bf6eb70ab016fc50e6a45c0ec970f5483626cccfb35ee53</originalsourceid><addsrcrecordid>eNpVkU1v3CAQhq2qVRNt8wd6qDj24g32AManqko_EilSL-0ZAR52iWzjAk61_z4ku40SDsOImXl4NW9VfWzoFkD2l85P07ptacu2DQjGqXhTnTdCsBralr19kZ9VFynd0XJYDwD8fXUGkndND_K8Wr75ZMM9xgMJjuiZ-HnABUuYM1lCiPUSw24OySeSVpMPCxKdUrBeZxzIP5_3JGPMXhfCeJiWffADSTmuNq8RU-ERE1GnTKyeLcYP1Tunx4QXp3tT_fnx_ffVdX376-fN1dfb2rKW5tpZBw6s7hy6FqRzYJxA01FtaCOc5RSFZtxStH1HHWcSRCustc4AR-SwqW6O3CHoO7VEPxWFKmivnh5C3CldZNsRFXea9860g-CaSYOaYQfYmb6xknUl31RfjqxlNRMOtuwm6vEV9HVl9nu1C_eqob3sOkEL4fOJEMPfFVNWU9k7jqOeMaxJAQWgVNJGltb22GpjSCmie_6noerRevVkvXq0Xp2sL0OfXip8HvlvNDwATMmwgQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3033008018</pqid></control><display><type>article</type><title>Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer</title><source>PubMed Central (Training)</source><creator>Liu, Ruiqi ; Huang, Xiaoqian ; Yang, Shiwei ; Du, Wenbo ; Chen, Xiaozhou ; Li, Huamei</creator><creatorcontrib>Liu, Ruiqi ; Huang, Xiaoqian ; Yang, Shiwei ; Du, Wenbo ; Chen, Xiaozhou ; Li, Huamei</creatorcontrib><description>Tertiary lymphoid structures (TLSs) are ectopic lymphoid formations that arise in non-lymphoid tissues due to chronic inflammation. The pivotal function of TLSs in regulating tumor invasion and metastasis has been established across several cancers, such as lung cancer, liver cancer, and melanoma, with a positive correlation between increased TLS presence and improved prognosis. Nevertheless, the current research about the clinical significance of TLSs in breast cancer remains limited. In our investigation, we discovered TLS-critical genes that may impact the prognosis of breast cancer patients, and categorized breast cancer into three distinct subtypes based on critical gene expression profiles, each exhibiting substantial differences in prognosis (p = 0.0046, log-rank test), with Cluster 1 having the best prognosis, followed by Cluster 2, and Cluster 3 having the worst prognosis. We explored the impact of the heterogeneity of these subtypes on patient prognosis, the differences in the molecular mechanism, and their responses to drug therapy and immunotherapy. In addition, we designed a machine learning-based classification model, unveiling highly consistent prognostic distinctions in several externally independent cohorts. A notable marker gene CXCL13 was identified in Cluster 3, potentially pivotal in enhancing patient prognosis. At the single-cell resolution, we delved into the adverse prognosis of Cluster 3, observing an enhanced interaction between fibroblasts, myeloid cells, and basal cells, influencing patient prognosis. Furthermore, we identified several significantly upregulated genes (CD46, JAG1, IL6, and IL6R) that may positively correlate with cancer cells' survival and invasive capabilities in this subtype. Our study is a robust foundation for precision medicine and personalized therapy, presenting a novel perspective for the contemporary classification of breast cancer.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2024.1364506</identifier><identifier>PMID: 38571938</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Female ; Humans ; Immunology ; Liver Neoplasms ; Lung Neoplasms - pathology ; Prognosis ; subtypes ; tertiary lymphoid structures ; Tertiary Lymphoid Structures - pathology ; tumor microenvironment</subject><ispartof>Frontiers in immunology, 2024-03, Vol.15, p.1364506-1364506</ispartof><rights>Copyright © 2024 Liu, Huang, Yang, Du, Chen and Li.</rights><rights>Copyright © 2024 Liu, Huang, Yang, Du, Chen and Li 2024 Liu, Huang, Yang, Du, Chen and Li</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c420t-fcf3f3ca7fef238ff3bf6eb70ab016fc50e6a45c0ec970f5483626cccfb35ee53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10987760/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10987760/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38571938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Ruiqi</creatorcontrib><creatorcontrib>Huang, Xiaoqian</creatorcontrib><creatorcontrib>Yang, Shiwei</creatorcontrib><creatorcontrib>Du, Wenbo</creatorcontrib><creatorcontrib>Chen, Xiaozhou</creatorcontrib><creatorcontrib>Li, Huamei</creatorcontrib><title>Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Tertiary lymphoid structures (TLSs) are ectopic lymphoid formations that arise in non-lymphoid tissues due to chronic inflammation. The pivotal function of TLSs in regulating tumor invasion and metastasis has been established across several cancers, such as lung cancer, liver cancer, and melanoma, with a positive correlation between increased TLS presence and improved prognosis. Nevertheless, the current research about the clinical significance of TLSs in breast cancer remains limited. In our investigation, we discovered TLS-critical genes that may impact the prognosis of breast cancer patients, and categorized breast cancer into three distinct subtypes based on critical gene expression profiles, each exhibiting substantial differences in prognosis (p = 0.0046, log-rank test), with Cluster 1 having the best prognosis, followed by Cluster 2, and Cluster 3 having the worst prognosis. We explored the impact of the heterogeneity of these subtypes on patient prognosis, the differences in the molecular mechanism, and their responses to drug therapy and immunotherapy. In addition, we designed a machine learning-based classification model, unveiling highly consistent prognostic distinctions in several externally independent cohorts. A notable marker gene CXCL13 was identified in Cluster 3, potentially pivotal in enhancing patient prognosis. At the single-cell resolution, we delved into the adverse prognosis of Cluster 3, observing an enhanced interaction between fibroblasts, myeloid cells, and basal cells, influencing patient prognosis. Furthermore, we identified several significantly upregulated genes (CD46, JAG1, IL6, and IL6R) that may positively correlate with cancer cells' survival and invasive capabilities in this subtype. Our study is a robust foundation for precision medicine and personalized therapy, presenting a novel perspective for the contemporary classification of breast cancer.</description><subject>breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunology</subject><subject>Liver Neoplasms</subject><subject>Lung Neoplasms - pathology</subject><subject>Prognosis</subject><subject>subtypes</subject><subject>tertiary lymphoid structures</subject><subject>Tertiary Lymphoid Structures - pathology</subject><subject>tumor microenvironment</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1v3CAQhq2qVRNt8wd6qDj24g32AManqko_EilSL-0ZAR52iWzjAk61_z4ku40SDsOImXl4NW9VfWzoFkD2l85P07ptacu2DQjGqXhTnTdCsBralr19kZ9VFynd0XJYDwD8fXUGkndND_K8Wr75ZMM9xgMJjuiZ-HnABUuYM1lCiPUSw24OySeSVpMPCxKdUrBeZxzIP5_3JGPMXhfCeJiWffADSTmuNq8RU-ERE1GnTKyeLcYP1Tunx4QXp3tT_fnx_ffVdX376-fN1dfb2rKW5tpZBw6s7hy6FqRzYJxA01FtaCOc5RSFZtxStH1HHWcSRCustc4AR-SwqW6O3CHoO7VEPxWFKmivnh5C3CldZNsRFXea9860g-CaSYOaYQfYmb6xknUl31RfjqxlNRMOtuwm6vEV9HVl9nu1C_eqob3sOkEL4fOJEMPfFVNWU9k7jqOeMaxJAQWgVNJGltb22GpjSCmie_6noerRevVkvXq0Xp2sL0OfXip8HvlvNDwATMmwgQ</recordid><startdate>20240320</startdate><enddate>20240320</enddate><creator>Liu, Ruiqi</creator><creator>Huang, Xiaoqian</creator><creator>Yang, Shiwei</creator><creator>Du, Wenbo</creator><creator>Chen, Xiaozhou</creator><creator>Li, Huamei</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240320</creationdate><title>Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer</title><author>Liu, Ruiqi ; Huang, Xiaoqian ; Yang, Shiwei ; Du, Wenbo ; Chen, Xiaozhou ; Li, Huamei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-fcf3f3ca7fef238ff3bf6eb70ab016fc50e6a45c0ec970f5483626cccfb35ee53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunology</topic><topic>Liver Neoplasms</topic><topic>Lung Neoplasms - pathology</topic><topic>Prognosis</topic><topic>subtypes</topic><topic>tertiary lymphoid structures</topic><topic>Tertiary Lymphoid Structures - pathology</topic><topic>tumor microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Ruiqi</creatorcontrib><creatorcontrib>Huang, Xiaoqian</creatorcontrib><creatorcontrib>Yang, Shiwei</creatorcontrib><creatorcontrib>Du, Wenbo</creatorcontrib><creatorcontrib>Chen, Xiaozhou</creatorcontrib><creatorcontrib>Li, Huamei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Ruiqi</au><au>Huang, Xiaoqian</au><au>Yang, Shiwei</au><au>Du, Wenbo</au><au>Chen, Xiaozhou</au><au>Li, Huamei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2024-03-20</date><risdate>2024</risdate><volume>15</volume><spage>1364506</spage><epage>1364506</epage><pages>1364506-1364506</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Tertiary lymphoid structures (TLSs) are ectopic lymphoid formations that arise in non-lymphoid tissues due to chronic inflammation. The pivotal function of TLSs in regulating tumor invasion and metastasis has been established across several cancers, such as lung cancer, liver cancer, and melanoma, with a positive correlation between increased TLS presence and improved prognosis. Nevertheless, the current research about the clinical significance of TLSs in breast cancer remains limited. In our investigation, we discovered TLS-critical genes that may impact the prognosis of breast cancer patients, and categorized breast cancer into three distinct subtypes based on critical gene expression profiles, each exhibiting substantial differences in prognosis (p = 0.0046, log-rank test), with Cluster 1 having the best prognosis, followed by Cluster 2, and Cluster 3 having the worst prognosis. We explored the impact of the heterogeneity of these subtypes on patient prognosis, the differences in the molecular mechanism, and their responses to drug therapy and immunotherapy. In addition, we designed a machine learning-based classification model, unveiling highly consistent prognostic distinctions in several externally independent cohorts. A notable marker gene CXCL13 was identified in Cluster 3, potentially pivotal in enhancing patient prognosis. At the single-cell resolution, we delved into the adverse prognosis of Cluster 3, observing an enhanced interaction between fibroblasts, myeloid cells, and basal cells, influencing patient prognosis. Furthermore, we identified several significantly upregulated genes (CD46, JAG1, IL6, and IL6R) that may positively correlate with cancer cells' survival and invasive capabilities in this subtype. Our study is a robust foundation for precision medicine and personalized therapy, presenting a novel perspective for the contemporary classification of breast cancer.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>38571938</pmid><doi>10.3389/fimmu.2024.1364506</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2024-03, Vol.15, p.1364506-1364506
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5fa59fb2d65a48bea4e73e7b91c847e7
source PubMed Central (Training)
subjects breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Female
Humans
Immunology
Liver Neoplasms
Lung Neoplasms - pathology
Prognosis
subtypes
tertiary lymphoid structures
Tertiary Lymphoid Structures - pathology
tumor microenvironment
title Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A16%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20an%20independent%20poor-prognosis%20subtype%20associated%20with%20tertiary%20lymphoid%20structures%20in%20breast%20cancer&rft.jtitle=Frontiers%20in%20immunology&rft.au=Liu,%20Ruiqi&rft.date=2024-03-20&rft.volume=15&rft.spage=1364506&rft.epage=1364506&rft.pages=1364506-1364506&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2024.1364506&rft_dat=%3Cproquest_doaj_%3E3033008018%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-fcf3f3ca7fef238ff3bf6eb70ab016fc50e6a45c0ec970f5483626cccfb35ee53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3033008018&rft_id=info:pmid/38571938&rfr_iscdi=true